HERG Screening Market Growth Is Accelerating As Industry Transformation Continues
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
HERG Screening Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The herg screening market has experienced rapid expansion in recent years, with its size projected to increase from $1.84 billion in 2025 to $2.06 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.0%. This historic growth has been driven by several factors, including a growing number of cardiac-related drug withdrawals, heightened investments in preclinical safety studies, an expansion in pharmaceutical research and development, wider adoption of in-vitro ion channel assays, and rising awareness surrounding drug-induced arrhythmias.
The hERG screening sector is forecasted to experience rapid expansion in the coming years, reaching a valuation of $3.21 billion by 2030, with a compound annual growth rate (CAGR) of 11.7%. Several factors are driving this growth in the projected timeframe, including progress in AI-based predictive toxicology, the adoption of organ-on-chip technologies, the rise of biologics and personalized medicine, increased outsourcing to contract development and manufacturing organizations (CDMOs), and the broadening of preclinical research activities in emerging markets. Key developments shaping the period ahead involve sophisticated cardiotoxicity modeling, automation of high-throughput screening processes, the integration of predictive analytics into preclinical safety assessments, the growth of contract research services, and the deployment of miniaturized microfluidic assays.
Download A Free Sample Report For Comprehensive Market Insights:
HERG Screening Market Expansion Supported By Key Demand Factors
The growing prevalence of heart disorders is expected to drive the expansion of the HERG screening market in the coming years. Heart disorders, also referred to as cardiovascular diseases or conditions, encompass a variety of issues that affect the heart and blood vessels. These conditions can impair the heart’s normal function and lead to severe health problems, often stemming from unhealthy lifestyle choices, an aging demographic, genetic predispositions, diabetes, and metabolic syndrome. HERG screening plays a crucial role in identifying potential drug candidates, reducing the risk of adverse cardiac events that might cause life-threatening arrhythmias such as torsade de pointes (TdP), and enhancing patient outcomes. For example, in October 2025, the Australian Institute of Health and Welfare, a government agency based in Australia, noted that in 2023, approximately 57,100 adults aged 25 and older experienced acute coronary events, averaging around 156 occurrences each day. Consequently, the increasing number of patients with heart disorders is fueling the growth of the HERG screening market.
The increase in the aging population is anticipated to fuel the growth of the HERG screening market moving forward. An aging population is characterized by a growing share of older people in a society, driven by longer life expectancies and lower birth rates. This demographic shift is occurring due to improved healthcare advancements that extend lifespan. HERG screening supports the aging population by ensuring that new medications are safe for elderly individuals, as it identifies compounds that may trigger dangerous cardiac side effects. For instance, in January 2024, the Population Reference Bureau, a US-based nonprofit organization, reported that the number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, reflecting a 47% rise. Consequently, this age group’s share of the total U.S. population is expected to grow from 17% to 23% over that timeframe. Thus, the rise in the aging population is driving the growth of the HERG screening market.
HERG Screening Market Segments: Where Are The Largest Growth Opportunities?
The herg screening market covered in this report is segmented –
1) By Type: Gene KCNH2, Mutant KCNH2
2) By Ion Channel: Voltage-Gated, Ligand Gated
3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications
Subsegments:
1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2
2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations
HERG Screening Market Growth Trends Influencing Competitive Dynamics
Leading industry players in the hERG screening market are placing significant emphasis on introducing innovative, advanced solutions—particularly GLP-certified hERG screening services—aimed at improving cardiac safety evaluations during drug development. Such a service involves conducting good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) through the standard whole-cell patch-clamp technique. This approach guarantees that screening procedures align with regulatory standards like ICH S7A and ICH S7B, crucial for safety pharmacology studies in the drug development process. For example, in August 2023, Metrion Biosciences Ltd., a pharmaceutical firm based in the UK, unveiled a GLP-certified hERG screening service. Designed to strengthen Metrion’s support for small-molecule therapeutic development, this offering also expands the company’s existing cardiac safety service portfolio. Moreover, the service employs the conventional whole-cell patch-clamp method to identify potential cardiac risks before human Phase 1 clinical trials, offers regulatory advice for safety pharmacology studies, and delivers high-quality biology services focused on ion channel targets to clients.
HERG Screening Market Major Participants And Competitive Dynamics
Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.
Access The Complete HERG Screening Market Report:
HERG Screening Market Geographic Distribution And Regional Opportunities
North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
